首页> 外文期刊>Stem cells international >In Vivo Tracking of Cell Therapies for Cardiac Diseases with Nuclear Medicine
【24h】

In Vivo Tracking of Cell Therapies for Cardiac Diseases with Nuclear Medicine

机译:体内跟踪核医学心脏病的细胞疗法

获取原文
获取原文并翻译 | 示例
           

摘要

Even though heart diseases are amongst the main causes of mortality and morbidity in the world, existing treatments are limited in restoring cardiac lesions. Cell transplantations, originally developed for the treatment of hematologic ailments, are presently being explored in preclinical and clinical trials for cardiac diseases. Nonetheless, little is known about the possible efficacy and mechanisms for these therapies and they are the center of continuous investigation. In this scenario, noninvasive imaging techniques lead to greater comprehension of cell therapies. Radiopharmaceutical cell labeling, firstly developed to track leukocytes, has been used successfully to evaluate the migration of cell therapies for myocardial diseases. A substantial rise in the amount of reports employing this methodology has taken place in the previous years. We will review the diverse radiopharmaceuticals, imaging modalities, and results of experimental and clinical studies published until now. Also, we report on current limitations and potential advances of radiopharmaceutical labeling for cell therapies in cardiac diseases.
机译:尽管心脏病是世界上死亡率和发病率的主要原因,但现有的治疗是有限的恢复心脏病变。目前正在探讨用于治疗血液学疾病的细胞移植,在心脏病的临床前和临床试验中探讨。尽管如此,对这些疗法可能的功效和机制很少,它们是连续调查的中心。在这种情况下,非侵入性成像技术导致对细胞疗法的更大理解。首先开发出追踪白细胞的放射性药物细胞标记已成功用于评估细胞疗法对心肌疾病的迁移。在前几年发生了雇用这种方法的报告数量的大幅增加。我们将审查不同的放射性药物,成像型号和实验和临床研究的结果,直到现在。此外,我们报告了对心脏病细胞疗法的放射性药物标记的当前限制和潜在进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号